Africa’s first-ever phase 1 trial of a long-acting injectable for malaria prevention launches in Rwanda
To eliminate malaria, we will need not only wider access to today’s tools but also the next generation of prevention technologies, said Dr Martin Fitchet, Chief Executive Officer of MMV.

